News & Events

News related to Afinion can be found here together with information on congresses or exhibitions where the Afinion will feature.

Update on albumin/creatinine ratio (ACR) CLIA-waived status

Tue, 21 Dec 2010

Dundee, Scotland, 21 December 2010: Axis-Shield (LSE:ASD, OSE:ASD), the innovative international in vitro diagnostics company, today announces that, following an application originally filed in February 2009, the US Food and Drug Administration (FDA) has indicated that Axis-Shield’s application for CLIA-waived status on the Afinion Albumin/Creatinine Ratio (ACR) has been denied, although the test is cleared under the US FDA’s 510(k) procedure and currently marketed to US customers having CLIA-accredited facilities. This will have no material impact on Axis-Shield’s forecasted sales and following this outcome Axis-Shield will continue to market the ACR test on Afinion in the USA.   

Axis-Shield Named Vendor of the Year by PSS in USA

Mon, 05 Oct 2009

Axis-Shield plc has been named “Vendor of the Year” by PSS (Physician Sales & Service), the largest distributor of medical supplies and services to office-based physicians in the United States.

Axis-Shield plc, Interim Results for the Six Months ended 30 June 2009

Thu, 24 Sep 2009

Axis-Shield plc announces its interim results for the six months ended 30 June 2009

Afinion Performance Affirmed In New Publication

Thu, 19 Mar 2009

Dundee, Scotland, 18 March 2009: Axis-Shield plc (LSE:ASD, OSE:ASD), the international in-vitro diagnostics (IVD) company, today announces that a new paper has been published confirming the performance of its Afinion Point-of-Care System and the assay for HbA1c, used to monitor efficacy of blood glucose control in diabetes.

Axis-Shield Afinion HbA1c Patent Granted In Japan

Wed, 15 Oct 2008

Axis-Shield have received notice of approval for its Japanese patent application governing the measuring methodology for HbA1c within the Afinion cassette for detection of this important marker of diabetic patient compliance.